PathAI, Summit Clinical partner for NASH trial services

By LabPulse.com staff writers

September 22, 2021 -- PathAI recently entered a partnership with Summit Clinical Research that will launch a clinical trial services solution for developers of drugs to treat nonalcoholic steatohepatitis (NASH).

The collaboration builds on PathAI's development of tools powered by artificial intelligence (AI) for evaluation of liver pathology, as well as Summit's expertise in NASH drug development and accelerated study execution.

The collaboration provides sponsors with an offering tailored to NASH sponsors featuring trial design, site activation and patient enrollment, and wet lab, diagnostic, and AI-pathology deployment services, the companies said.

The companies also said they have contracted with a sponsor to provide pathology services for a phase II clinical trial, with several additional trials under negotiation.

PathAI buys Poplar Healthcare
Pathology artificial intelligence software developer PathAI has purchased Poplar, the management service organization of Poplar Healthcare, an anatomic...
Venture capital funding for digital pathology tops $860M
While 2014-2017 reflected a relatively quiet period for investment in digital pathology, over the last three years there has been a significant uptick...
PathAI reports algorithm on par in PD-L1 immunotherapy studies
PathAI reported that its pathology artificial intelligence algorithm performed on par or better than board-certified pathologists in retrospective immunotherapy...
Pathology AI developer PathAI raises $60M
Pathology artificial intelligence (AI) software developer PathAI has raised $60 million in a series B funding round.

Copyright © 2021 LabPulse.com

Last Updated ls 9/22/2021 9:14:01 AM